Detail akcie Processa Rg online

Business Summary: Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Processa Pharmaceuticals Inc revenues was not reported. Net loss increased 12% to $10.2M. Higher net loss reflects Research and development expenses increase of 9% to $4.4M (expense), General and administrative increase of 65% to $568K (expense), Interest Income decrease of 58% to $82K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$78.69 to -$15.56.